TECTONIC THERAPEUTIC, INC. Proceeds from Issuance of Redeemable Convertible Preferred Stock
TECTONIC THERAPEUTIC, INC. (TECX) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $58.26 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2020-03-16
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2018-12-31 was -$1.00K, a 100.01% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2018-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2018-06-30 was -$5.00K.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2018-03-31 was $58.26M.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2018 was $58.26M, a 234.52% increase from fiscal 2017.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2017 was $17.41M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 6 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 9 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$1.00K derived: sum of 2 quarters · filed 2020-03-16 | -$6.00K derived: sum of 3 quarters · filed 2020-03-16 | $58.26M 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$5.00K derived: sum of 2 quarters · filed 2019-11-07 | $58.26M 10-Q · filed 2019-11-07 | $72.22M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $58.26M 10-Q · filed 2019-08-08 | $72.22M derived: sum of 3 quarters · filed 2019-08-08 | $72.20M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $58.26M 10-Q · filed 2019-05-13 | $72.23M derived: sum of 2 quarters · filed 2019-05-13 | $72.21M derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $13.97M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | $13.95M derived: sum of 2 quarters · filed 2019-03-25 | $17.41M 10-K · filed 2019-03-25 | |
| 2017-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $3.45M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $3.47M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |